Literature DB >> 8773599

Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.

B C Jacobs1, P A van Doorn, P I Schmitz, A P Tio-Gillen, P Herbrink, L H Visser, H Hooijkass, F G van der Meché.   

Abstract

The group of patients with Guillain-Barr'e syndrome (GBS) is very heterogenous with regard to antecedent infections, immunological parameters, clinical manifestations, and response to treatment. In this study, the presumed pathogenic factors anti-GM1 antibodies and Campylobacter jejuni infections were related to the clinical characteristics. Serum from 154 patients with GBS, 63 patients with other neurological diseases (OND), and 50 normal controls (NC) were tested for the presence of antibodies against GM1 and C. jejuni. Anti-GM1 antibodies were detected in 31 (20%) GBS patients, 5 (8%) OND patients, and in none of the NC. Evidence for a recent C. jejuni infection was found in 49 (32%) GBS patients and less often in OND patients (11%) or NC (8%). In GBS patients, the presence of anti-GM1 antibodies was significantly associated with C. jejuni infections. The subgroup of GBS patients with anti-GM1 antibodies suffered more often from a rapidly progressive and more severe neuropathy with predominantly distal distribution of weakness, without deficits of cranial nerves or sensory disturbances. The subgroup with C. jejuni infection also more often had a severe pure motor variant of GBS. Recovery of the patients with anti-GM1 antibodies and C. jejuni infections was not as good after plasma exchange compared with intravenous immunoglobulins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8773599     DOI: 10.1002/ana.410400209

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.

Authors:  H P Endtz; C W Ang; N van Den Braak; B Duim; A Rigter; L J Price; D L Woodward; F G Rodgers; W M Johnson; J A Wagenaar; B C Jacobs; H A Verbrugh; A van Belkum
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes.

Authors:  Nobuhiro Yuki; Norito Kokubun; Satoshi Kuwabara; Yukari Sekiguchi; Masafumi Ito; Masaaki Odaka; Koichi Hirata; Francesca Notturno; Antonino Uncini
Journal:  J Neurol       Date:  2011-12-06       Impact factor: 4.849

5.  Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients.

Authors:  Christiane Caudie; Arnaud Quittard Pinon; Didier Taravel; Valérie Sivadon-Tardy; David Orlikowski; Flore Rozenberg; Tarek Sharshar; Jean Claude Raphaël; Jean Louis Gaillard
Journal:  J Neurol       Date:  2011-04-24       Impact factor: 4.849

6.  Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey.

Authors: 
Journal:  J Neurol       Date:  2003-05       Impact factor: 4.849

Review 7.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

8.  The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome.

Authors:  Peggy C R Godschalk; Astrid P Heikema; Michel Gilbert; Tomoko Komagamine; C Wim Ang; Jobine Glerum; Denis Brochu; Jianjun Li; Nobuhiro Yuki; Bart C Jacobs; Alex van Belkum; Hubert P Endtz
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Modulation of IgG-FcRn interactions to overcome antibody-mediated inhibition of nerve regeneration.

Authors:  Gang Zhang; Jianxin Lin; Sameera Ghauri; Kazim A Sheikh
Journal:  Acta Neuropathol       Date:  2017-05-30       Impact factor: 17.088

10.  Bacterial colitis.

Authors:  Harry T Papaconstantinou; J Scott Thomas
Journal:  Clin Colon Rectal Surg       Date:  2007-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.